Literature DB >> 8551730

Prognostic evaluation of lymphadenectomy for epithelial ovarian cancer.

F Kikkawa1, H Ishikawa, K Tamakoshi, N Suganuma, K Mizuno, M Kawai, Y Arii, A Tamakoshi, K Kuzuya, Y Tomoda.   

Abstract

Between 1989 and 1991, 150 patients with ovarian cancer were treated with chemotherapy, including cisplatin, in the Tokai Ovarian Tumor Study Group. Of these patients, 25 underwent cytoreductive surgery with lymphadenectomy, including removal of either pelvic or para-aortic lymph nodes, and 36 underwent both lymphadenectomies. A significant difference was observed between survival curves of the groups with positive and negative lymph nodes, respectively (P = 0.0049). The overall survival was longer in the lymphadenectomy group than in the nonlymphadenectomy group (P = 0.0842), and a significantly longer survival time was noted for stage III patients who underwent lymphadenectomy compared with those who did not (P = 0.0185). Multivariate analysis demonstrated that lymphadenectomy is a positive prognostic factor. The authors conclude that both pelvic and para-aortic lymph nodes should be resected to improve survival as well as to assess exact staging in patients with ovarian cancer.

Entities:  

Mesh:

Year:  1995        PMID: 8551730     DOI: 10.1002/jso.2930600403

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  5 in total

1.  Increased matrix metalloproteinase-9 activity in human ovarian cancer cells cultured with conditioned medium from human peritoneal tissue.

Authors:  K Shibata; F Kikkawa; A Nawa; K Tamakoshi; N Suganuma; Y Tomoda
Journal:  Clin Exp Metastasis       Date:  1997-11       Impact factor: 5.150

2.  The relationship between retroperitoneal lymphadenectomy and survival in advanced ovarian cancer patients.

Authors:  Chenyan Fang; Yingli Zhang; Lingqin Zhao; Xi Chen; Liang Xia; Ping Zhang
Journal:  BMC Cancer       Date:  2020-07-13       Impact factor: 4.430

3.  Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial.

Authors:  T Dell' Anna; M Signorelli; P Benedetti-Panici; A Maggioni; R Fossati; R Fruscio; R Milani; L Bocciolone; A Buda; C Mangioni; G Scambia; R Angioli; E Campagnutta; R Grassi; F Landoni
Journal:  Br J Cancer       Date:  2012-08-02       Impact factor: 7.640

4.  Role of primary surgery in advanced ovarian cancer.

Authors:  Karsten Münstedt; Folker E Franke
Journal:  World J Surg Oncol       Date:  2004-10-02       Impact factor: 2.754

5.  The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients.

Authors:  J K Chan; R Urban; J M Hu; J Y Shin; A Husain; N N Teng; J S Berek; K Osann; D S Kapp
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.